Financial information
Read our latest press releases, financial reports and annual meeting materials.

Why Invest
The digitalisation of healthcare will be crucial able to meet the healthcare requirements of the future. In addition to the challenges that Covid-19 has brought with it, we are now seeing increasing patient volumes and limited financial resources in the healthcare sector. For an efficient and safe care, we need new ways of working and new technical innovations. As part of the development, more and more ambulance operations are switching over to electronic patient records and introducing systems that allow patient information to be shared in real time throughout the care chain. Primary care has also begun to implement solutions to be able to monitor and treat patients remotely to a greater extent. Developments in this segment for modern e-health solutions are progressing and are expected to accelerate in the coming years.
Ortivus has in-house development and production of monitoring equipment and is well equipped to meet the requirements of modern, adaptable and reliable healthcare solutions. With Ortivus’ MobiMed, you can review a patients’ vital sign such as ECG, blood pressure and heart rate in real time and at a distance. MobiMed facilitates diagnosis through advanced decision support and the ability to consult an expert remotely via video call or chat. With MobiMed, treatment can be started at an early stage while unnecessary hospital transports can be avoided as a large part of the care can take place outside the hospital. With its modularity, flexibility and advanced features, MobiMed is well adapted for our future healthcare.
Ortivus is today established in many countries and is well positioned to take MobiMed to an even larger international market.
Ortivus shares have been listed on the NASDAQ Stockholm Small Cap-list since January 2, 1997.
Stock Symbol | ISIN | Shares Outstanding | Votes/share | Total Number of Votes | |
---|---|---|---|---|---|
Class A | ORTI A | SE0000188930 | 1,662,682 | 10 | 16,626,820 |
Class B | ORTI B | SE0000123085 | 42,644,786 | 1 | 42,644,786 |
The share capital is SEK 15,507,614. Share capital is divided between class A and class B shares. The number of shares outstanding is 44,307,468 of which class A amount to 1,662,682 and class B to 42,644,786. Every class A share carries 10 votes and every class B share carries one vote.
Ortivus A
Ortivus B
Hover the mouse over the graphs to see the share price at the corresponding date.
Ortivus’ Investors
Top 10 investors | A-Shares | B-Shares | Number of Votes | Number of Shares | Share of Capital | Share of Votes |
---|---|---|---|---|---|---|
Ponderus Invest AB | 20 624 | 10 320 748 | 10 526 988 | 10 341 372 | 23.3% | 17.8% |
Nordnet Pensionsförsäkring | 148 601 | 4 013 435 | 5 499 445 | 4 162 036 | 9.4% | 9.3% |
Försäkringsaktiebolaget Avanza Pension | 38 517 | 3 459 685 | 3 844 855 | 3 498 202 | 7.9% | 6.5% |
Konstatin Papaxanthis | 250 000 | 2 500 000 | 250 000 | 0.6% | 4.2% | |
Pär-Ola Adolfsson | 52 459 | 1 818 836 | 2 343 426 | 1 871 295 | 4.2% | 4.0% |
Ing-Marie Fraim | 2 071 704 | 2 071 704 | 2 071 704 | 4.7% | 3.5% | |
Raspart Förvaltning AB | 1 820 000 | 1 820 000 | 1 820 000 | 4.1% | 3.1% | |
CBLDN-Phoneix Fund | 1 581 045 | 1 581 045 | 1 581 045 | 3.6% | 2.7% | |
Nils-Arne Eriksson | 1 550 625 | 1 550 625 | 1 550 625 | 3.5% | 2.6% | |
Malin Pettersson | 961 245 | 961 245 | 961 245 | 2.2% | 1.6% | |
Other | 1 152 238 | 15 047 463 | 26 569 843 | 16 199 701 | 36.6% | 44.8% |
Total | 1 662 439 | 42 644 786 | 59 269 176 | 44 307 225 | 100% | 100% |

Financial Reports
Yearly Reports
Quarterly Reports
Subscribe to Financial Information

IR Calendar
- Interim report Q2 2022: 25/8 2022, 08:30 am
- Interim report Q3 2022: 11/11 2022, 08:30 am
- Year-end report Q4 2022: 17/2 2023, 08:30 am
- Interim report Q1 2023: 21/4 2023, 08:30 am
Latest news

ORTIVUS ARE WELCOMING KLARA AS ORDER MANAGEMENT SPECIALIST!
Read More
Ortivus is awarded a contract regarding the delivery of defibrillators to Region Västmanland
Read More
Ortivus is looking for a Sales & Marketing Associate
Read More